Sofinnova Partners

Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.

Since their founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade.  They are a clinical-stage biopharmaceutical investment firm with approximately $3.0B in assets under management and committed capital. They invest in both private and public equity of therapeutics-focused companies. 

Their Mission: to improve the lives of patients through science. They strive to provide outstanding results for those we serve: patients, entrepreneurs, and the investors that entrust us with their capital.

Sofinnova invests in late preclinical and clinical therapeutic companies across the U.S. and Europe. Key therapeutic areas include oncology, respiratory, dermatology, ophthalmology, neurology and women’s health. They actively partner with entrepreneurs in both the U.S. and Europe who want to rewrite the quality of healthcare today for a better life tomorrow.

Sofinnova has raised €650 million for Fund XI, bringing its total capital raised to €1.5 billion. The fund will invest in 50 to 60 new companies, fueling the next wave of innovation in biotech and medtech.

Portfolio: Alcon, Afyx, Amarin, Apellis.